Cargando…
Development of a screening platform to discover natural products active against SARS-CoV-2 infection using lung organoid models
BACKGROUND: Natural products can serve as one of the alternatives, exhibiting high potential for the treatment and prevention of COVID-19, caused by SARS-CoV-2. Herein, we report a screening platform to test the antiviral efficacy of a natural product library against SARS-CoV-2 and verify their acti...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974403/ https://www.ncbi.nlm.nih.gov/pubmed/36855173 http://dx.doi.org/10.1186/s40824-023-00357-y |
_version_ | 1784898718486495232 |
---|---|
author | Lee, Joo-Eun Jeong, Se Yun Li, Zijun Kim, Hyun-Yi Kim, Hyun-Woo Yoo, Min Jeong Jang, Hee Joo Kim, Do-Kyun Cho, Namki Yoo, Hee Min Kim, Ki Hyun |
author_facet | Lee, Joo-Eun Jeong, Se Yun Li, Zijun Kim, Hyun-Yi Kim, Hyun-Woo Yoo, Min Jeong Jang, Hee Joo Kim, Do-Kyun Cho, Namki Yoo, Hee Min Kim, Ki Hyun |
author_sort | Lee, Joo-Eun |
collection | PubMed |
description | BACKGROUND: Natural products can serve as one of the alternatives, exhibiting high potential for the treatment and prevention of COVID-19, caused by SARS-CoV-2. Herein, we report a screening platform to test the antiviral efficacy of a natural product library against SARS-CoV-2 and verify their activity using lung organoids. METHODS: Since SARS-CoV-2 is classified as a risk group 3 pathogen, the drug screening assay must be performed in a biosafety level 3 (BSL-3) laboratory. To circumvent this limitation, pseudotyped viruses (PVs) have been developed as replacements for the live SARS-CoV-2. We developed PVs containing spikes from Delta and Omicron variants of SARS-CoV-2 and improved the infection in an angiotensin-converting enzyme 2 (ACE2)-dependent manner. Human induced pluripotent stem cells (hiPSCs) derived lung organoids were generated to test the SARS-CoV-2 therapeutic efficacy of natural products. RESULTS: Flavonoids from our natural product library had strong antiviral activity against the Delta- or Omicron-spike-containing PVs without affecting cell viability. We aimed to develop strategies to discover the dual function of either inhibiting infection at the beginning of the infection cycle or reducing spike stability following SARS-CoV-2 infection. When lung cells are already infected with the virus, the active flavonoids induced the degradation of the spike protein and exerted anti-inflammatory effects. Further experiments confirmed that the active flavonoids had strong antiviral activity in lung organoid models. CONCLUSION: This screening platform will open new paths by providing a promising standard system for discovering novel drug leads against SARS-CoV-2 and help develop promising candidates for clinical investigation as potential therapeutics for COVID-19. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40824-023-00357-y. |
format | Online Article Text |
id | pubmed-9974403 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-99744032023-03-01 Development of a screening platform to discover natural products active against SARS-CoV-2 infection using lung organoid models Lee, Joo-Eun Jeong, Se Yun Li, Zijun Kim, Hyun-Yi Kim, Hyun-Woo Yoo, Min Jeong Jang, Hee Joo Kim, Do-Kyun Cho, Namki Yoo, Hee Min Kim, Ki Hyun Biomater Res Research Article BACKGROUND: Natural products can serve as one of the alternatives, exhibiting high potential for the treatment and prevention of COVID-19, caused by SARS-CoV-2. Herein, we report a screening platform to test the antiviral efficacy of a natural product library against SARS-CoV-2 and verify their activity using lung organoids. METHODS: Since SARS-CoV-2 is classified as a risk group 3 pathogen, the drug screening assay must be performed in a biosafety level 3 (BSL-3) laboratory. To circumvent this limitation, pseudotyped viruses (PVs) have been developed as replacements for the live SARS-CoV-2. We developed PVs containing spikes from Delta and Omicron variants of SARS-CoV-2 and improved the infection in an angiotensin-converting enzyme 2 (ACE2)-dependent manner. Human induced pluripotent stem cells (hiPSCs) derived lung organoids were generated to test the SARS-CoV-2 therapeutic efficacy of natural products. RESULTS: Flavonoids from our natural product library had strong antiviral activity against the Delta- or Omicron-spike-containing PVs without affecting cell viability. We aimed to develop strategies to discover the dual function of either inhibiting infection at the beginning of the infection cycle or reducing spike stability following SARS-CoV-2 infection. When lung cells are already infected with the virus, the active flavonoids induced the degradation of the spike protein and exerted anti-inflammatory effects. Further experiments confirmed that the active flavonoids had strong antiviral activity in lung organoid models. CONCLUSION: This screening platform will open new paths by providing a promising standard system for discovering novel drug leads against SARS-CoV-2 and help develop promising candidates for clinical investigation as potential therapeutics for COVID-19. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40824-023-00357-y. BioMed Central 2023-03-01 /pmc/articles/PMC9974403/ /pubmed/36855173 http://dx.doi.org/10.1186/s40824-023-00357-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Lee, Joo-Eun Jeong, Se Yun Li, Zijun Kim, Hyun-Yi Kim, Hyun-Woo Yoo, Min Jeong Jang, Hee Joo Kim, Do-Kyun Cho, Namki Yoo, Hee Min Kim, Ki Hyun Development of a screening platform to discover natural products active against SARS-CoV-2 infection using lung organoid models |
title | Development of a screening platform to discover natural products active against SARS-CoV-2 infection using lung organoid models |
title_full | Development of a screening platform to discover natural products active against SARS-CoV-2 infection using lung organoid models |
title_fullStr | Development of a screening platform to discover natural products active against SARS-CoV-2 infection using lung organoid models |
title_full_unstemmed | Development of a screening platform to discover natural products active against SARS-CoV-2 infection using lung organoid models |
title_short | Development of a screening platform to discover natural products active against SARS-CoV-2 infection using lung organoid models |
title_sort | development of a screening platform to discover natural products active against sars-cov-2 infection using lung organoid models |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974403/ https://www.ncbi.nlm.nih.gov/pubmed/36855173 http://dx.doi.org/10.1186/s40824-023-00357-y |
work_keys_str_mv | AT leejooeun developmentofascreeningplatformtodiscovernaturalproductsactiveagainstsarscov2infectionusinglungorganoidmodels AT jeongseyun developmentofascreeningplatformtodiscovernaturalproductsactiveagainstsarscov2infectionusinglungorganoidmodels AT lizijun developmentofascreeningplatformtodiscovernaturalproductsactiveagainstsarscov2infectionusinglungorganoidmodels AT kimhyunyi developmentofascreeningplatformtodiscovernaturalproductsactiveagainstsarscov2infectionusinglungorganoidmodels AT kimhyunwoo developmentofascreeningplatformtodiscovernaturalproductsactiveagainstsarscov2infectionusinglungorganoidmodels AT yoominjeong developmentofascreeningplatformtodiscovernaturalproductsactiveagainstsarscov2infectionusinglungorganoidmodels AT jangheejoo developmentofascreeningplatformtodiscovernaturalproductsactiveagainstsarscov2infectionusinglungorganoidmodels AT kimdokyun developmentofascreeningplatformtodiscovernaturalproductsactiveagainstsarscov2infectionusinglungorganoidmodels AT chonamki developmentofascreeningplatformtodiscovernaturalproductsactiveagainstsarscov2infectionusinglungorganoidmodels AT yooheemin developmentofascreeningplatformtodiscovernaturalproductsactiveagainstsarscov2infectionusinglungorganoidmodels AT kimkihyun developmentofascreeningplatformtodiscovernaturalproductsactiveagainstsarscov2infectionusinglungorganoidmodels |